Trial Profile
A retrospective single-institution cohort study investigating efficacy and tolerability of nivolumab, pembrolizumab or ipilimumab for advanced or metastatic melanoma elderly patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2018
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 02 Nov 2018 New trial record
- 01 Oct 2018 Results published in the Cancer Immunology Immunotherapy